EVMN

Business Context and Reporting Period

Company: Evommune, Inc. (EVMN)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Evommune is a clinical-stage biotechnology company developing therapies for chronic inflammatory diseases. The company focuses on two primary product candidates: EVO756 (an oral MRGPRX2 antagonist for chronic spontaneous urticaria and atopic dermatitis) and EVO301 (an IL-18BP fusion protein for atopic dermatitis and ulcerative colitis).
Public Status: The company completed its Initial Public Offering (IPO) on November 6, 2025, listing on the New York Stock Exchange. As of December 31, 2025, all convertible preferred stock had converted to common stock.

Key Financial Metrics

Note: Revenue consists entirely of license revenue. The company has no product sales revenue.

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 86% to $13.0 million, driven by $10.0 million in milestone revenue and $3.0 million in license revenue from the Maruho Japan Agreement.
• Expense Increases:
  • R&D: Increased 15% to $74.0 million, primarily due to higher clinical trial costs for EVO756 and increased discovery research expenses, partially offset by a decrease in EVO301 expenses (which included a $15.0 million upfront license fee in 2024).
  • G&A: Increased 57% to $20.0 million, driven by higher personnel costs, stock-based compensation ($4.5 million vs. $1.0 million), and IPO-related expenses.
• Other Income: Increased significantly to $12.2 million, largely due to an $8.9 million gain from the change in fair value of a convertible preferred stock forward upon settlement in June 2025.
• Liquidity: Cash and investments grew substantially to $216.7 million following the November 2025 IPO (net proceeds of $157.0 million) and a Series C preferred stock issuance ($65.2 million).

Guidance, Outlook, and Risks

Clinical Outlook & Milestones

• EVO756:
  • CSU: Phase 2b dose-ranging trial initiated April 2025; initial data expected Q2 2026.
  • AD: Phase 2b dose-ranging trial initiated August 2025; initial data expected H2 2026.
  • Migraine: Phase 2b trial planned for mid-2026.
• EVO301:
  • AD: Positive Phase 2a results announced February 2026 (met primary endpoint). Moving to Phase 2b subcutaneous trial.
  • UC: Evaluating potential Phase 2 trial.

Capital Requirements

Management expects existing cash and investments as of December 31, 2025, to fund operations through the second half of 2028. The company anticipates continued net losses as it advances clinical trials and expands operations.

Key Risks

• Clinical Failure: High risk that product candidates may fail to demonstrate safety or efficacy in later-stage trials.
• Capital Needs: Substantial additional funding will be required; failure to raise capital could force delays or termination of programs.
• Regulatory Approval: No products are approved; regulatory approval is uncertain and time-consuming.
• Third-Party Reliance: Dependence on third-party manufacturers (CDMOs) and CROs for development and supply.
• Intellectual Property: Reliance on in-licensed IP (Dermira, AprilBio); risk of license termination or infringement claims.

Investor Verification Checklist

• Cash Runway: Verify the $216.7 million cash balance and the specific assumptions used to project funding through H2 2028.
• Clinical Data: Review the full clinical data for the EVO756 Phase 2 CIndU trial and the EVO301 Phase 2a AD trial to assess the robustness of the reported efficacy.
• License Agreements: Examine the terms of the Dermira, Maruho, and AprilBio agreements for milestone payment obligations and royalty rates.
• Subsequent Events: Note the February 2026 private placement of common stock raising $125.3 million, which extends the company's liquidity beyond the 2025 year-end figures.
• Stock-Based Compensation: Monitor the impact of the new 2025 Equity Incentive Plan and the significant increase in stock-based compensation expense post-IPO.